Viral vectors are useful tools used by molecular biologists to deliver genetic material into cells. The Viral Vectors Market Analysis and Opportunities report reveals that viral vectors comprise a rising market that is expected to continue to grow as usage increases and novel technologies enter the market.
Viral vectors are the most effective means of gene transfer to modify specific cells or alter the expression of therapeutic genes. The choice of viral vector depends on the efficiency of transgene expression, ease of production, safety, toxicity, and stability. Viral vector technology is used in gene therapy and vaccines. It is an exciting and interesting time to be involved in the viral vector industry. Science is moving ahead and now the industry needs to industrialize and standardize the manufacturing and commercialization of products. The industry is moving in the direction of a standardized set-up and a closed automated system. This is especially true in gene therapy. Consequently, gene therapy products are transforming the treatment of cancers and genetic diseases. Viral vectors do not cause disease since they have been modified by removing the genes involved in replication and are replaced with therapeutic genes. Viral vectors are genetically stable, non-toxic for host cells and safe to handle.
Viruses attack the host and introduce genetic material as part of the replication cycle. The genetic material contains basic instructions for the cell to reproduce, hijacking the body’s normal production machinery to serve the needs of the virus. Thus, additional copies of the virus are produced leading to more cells becoming infected. Then why use viruses for gene therapy? - because viruses could be good vehicles to transport good genes into the human cell. Scientists remove the genes in the virus that cause disease and replace them with genes encoding the desired effect.
Many gene therapy clinical trials rely on retroviruses or adenoviruses to deliver the desired gene. Other viruses used as vectors include adeno-associated viruses, lentiviruses, pox viruses, alphaviruses, and herpes viruses. These viruses differ in how well they transfer genes to the cells they recognize and are able to infect, and whether they alter the cell’s DNA permanently or temporarily.
Viral vectors are defined by three components:
- the protein capsid and/or envelope
- the transgene of interest to produce the desired effect
- the regulatory cassette - which is combined elements that control stable or transient somatic expression of the transgene
Scope and Methodology
The analysis in this report, Viral Vectors Market Analysis and Opportunities, is based on the author’s industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of viral vector manufacturing companies, pharmaceutical and biotechnology companies, cell and gene therapy companies and research institutes. A combination of company, government, industry, institutional and private sources generate the primary sources of information. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.
All market data are based on manufacturer sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers’ level. The base year for data was 2021 with forecast data provided for 2026. Compound annual growth rates (CAGRs) are provided for the 2021-2026 periods for each segment covered. The forecasted market analysis for 2021-2026 is largely based on demographic trends, new developments, cell and gene therapy advancements, company performance trends, merger and acquisitions, and global expansion.
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARY
OVERVIEW
SCOPE AND METHODOLOGY
MARKET TRENDS
MARKET DRIVERS AND LIMITERS
- Table 1-1: Viral Vector Market Drivers and Limiters
MARKET SUMMARY
- Table 1-2: Total Viral Vector Market Revenues 2021-2026 (in millions$)
- Figure 1-1: Viral Vector Market Revenues, 2021-2026 ($ millions)
COMPETITIVE LANDSCAPE
CHAPTER 2: INTRODUCTION TO VIRAL VECTORS
OVERVIEW
- Table 2-1: Selected Examples of Viruses in Gene Therapy
TYPES OF VIRAL VECTORS
- Retrovirus
- Adenovirus
- HSV Virus
- Chimeric Virus
- Other
DISEASE PROFILES IN VIRAL VECTOR MARKETS
- Cancer
- Figure 2-1: Incidence of Cancer by Type, 2020
- Figure 2-2: Distribution of Cancer Incidence by Type, 2020
- Cardiovascular Disease
- Selected Blood and Genetic Disorders
- Infectious Diseases
CHAPTER 3: MARKET TRENDS
POPULATION AND AGING
- Table 3-1: Elderly Support Ratio in Various Countries (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
ELDERLY POPULATION
- Figure 3-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
GENE THERAPY AND VIRAL VECTOR USE
CANCER AND VIRAL VECTOR USE
INFECTIOUS DISEASE AND VIRAL VECTOR USE
TRANSDUCTION AND TRANSFECTION
- Transfection
- Transduction
COMPETING METHODS
- Electroporation
- Non-Viral
- Transposons
VIRAL VECTOR SHORTAGES
COVID-19 PLATFORMS AND VACCINES
- Table 3-2: Selected Viral Vector-based COVID-19 Vaccines
PRODUCTS IN DEVELOPMENT UTILIZING VIRAL VECTORS
- Table 3-3: Selected Products in Development Utilizing Viral Vectors
CHAPTER 4: MARKET ANALYSIS
- Table 4-1: Total Viral Vector Market Revenues 2021-2026 (in millions$)
- Figure 4-1: Viral Vector Market Revenues, 2021-2026 ($ millions)
VIRAL VECTOR MARKET BY VECTOR TYPE
- Table 4-2: Viral Vector Market by Vector Type 2021-2026 (in millions)
- Figure 4-2: Viral Vector Market Percentage by Type 2021
- Figure 4-3: Viral Vector Market Percentage by Type 2026
VIRAL VECTOR MARKET SHARE BY DISEASE
- Figure 4-4: Viral Vector Market Percentage by Disease, 2021
VIRAL VECTOR USE BY APPLICATION
- Figure 4-5: Viral Vector Market Use Percentage by Application 2021
VIRAL VECTOR WORKFLOW PROCESSING
- Figure 4-6: Viral Vector Upstream/Downstream Workflow Percentage, 2021
- Figure 4-7: Viral Vector Upstream/Downstream Workflow Percentage, 2026
VIRAL VECTOR MARKET BY REGION
- Table 4-3: Global Viral Vector Market Revenues by Geographic Region, 2021-2026 (in millions$)
- Figure 4-8: Global Viral Vector Market Percent by Geographic Region, 2021
- Figure 4-9: Global Viral Vector Market Percent by Geographic Region, 2026
CHAPTER 5: COMPETITORS
COMPETITIVE LANDSCAPE
- Figure 5-1: Viral Vector Manufacturing - Pharmaceutical/Biotech companies vs CDMOs - 2021
ALLIANCES, ACQUISITIONS AND COLLABORATIONS
- Table 5-1: Selected Mergers and Acquisitions of Viral Vector Companies
EXPANSION OF MANUFACTURING
- Table 5-2: Selected Recent Viral Vector Company Expansion
COMPETITOR ANALYSIS
CHAPTER 6: MARKET PARTICIPANT PROFILES
4D MOLECULAR THERAPEUTICS, INC. (4DMT)
- Table 6-1: 4DMT Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-2: 4DMT (2019-2020) ($ thousands)
ABL INC
- Table 6-3: ABL Corporate Summary
- Company Overview
- Products
AGC BIOLOGICS
- Table 6-4: AGC Biologics Technologies Corporate Summary
- Company Overview
- Products
AGILENT TECHNOLOGIES
- Table 6-5: Agilent Technologies Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-6: Agilent (2017-2020) ($ millions)
ALDEVRON
- Table 6-7: Aldevron Corporate Summary
- Company Overview
- Products
BATAVIA BIOSCIENCES B.V.
- Table 6-8: Batavia Biosciences Corporate Summary
- Company Overview
- Products
BIOVIAN OY
- Table 6-9: Biovian Corporate Summary
- Company Overview
- Products
CATAPULT CELL AND GENE THERAPY
- Table 6-10: Catapult Cell and Gene Therapy Corporate Summary
- Company Overview
- Products
CEVEC PHARMACEUTICALS GMBH
- Table 6-11: Cevec Pharmaceuticals Corporate Summary
- Company Overview
- Products
COBRA BIOLOGICS
- Table 6-12: Cobra Biologics Corporate Summary
- Company Overview
- Products
CYTIVA LIFE SCIENCES
- Table 6-13: Cytiva Corporate Summary
- Company Overview
- Products
GENEZEN
- Table 6-14: Genezen Corporate Summary
- Company Overview
- Products
HORIZON DISCOVERY LTD.
- Table 6-15: Horizon Discovery Corporate Summary
- Company Overview
- Products
FINVECTOR OY
- Table 6-16: FinVector Corporate Summary
- Company Overview
- Products
FUJIFILM DIOSYNTH BIOTECHNOLOGIES
- Table 6-17: FUJIFILM Diosynth Corporate Summary
- Company Overview
- Products
LONZA
- Table 6-18: Lonza Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-19: Lonza (2019-2020) ($ millions)
MERCK KGAA/ MILLIPORE SIGMA
- Table 6-20: Millipore Sigma Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-21: Merck/MilliporeSigma (2019-2020) ($ millions)
MIRUS BIO
- Table 6-22: Mirus Bio Corporate Summary
- Company Overview
- Products
OXFORD BIOMEDICA PLC.
- Table 6-23: Agilent Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-24: Oxford Biomedica (2019-2020) ($ millions)
REGENXBIO, INC
- Table 6-25: REGENXBIO Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-26: REGENXBIO (2019-2020) ($ thousands)
SANOFI S.A.
- Table 6-27: Sanofi S.A. Corporate Summary
- Company Overview
- Products
SIRION BIOTECH
- Table 6-28: SIRION Biotech Corporate Summary
- Company Overview
- Products
SPARK THERAPEUTICS, INC
- Table 6-29: Spark Therapeutics Corporate Summary
- Company Overview
- Products
TAKARA BIO
- Table 6-30: Takara Bio Corporate Summary
- Company Overview
- Products
THERMO FISHER SCIENTIFIC
- Table 6-31: Thermo Fisher Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-32: Thermo Fisher Scientific (2019-2020) ($ millions)
UNIQURE N.V.
- Table 6-33: uniQure Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-34: uniQure (2019-2020) ($ thousands)
VECTOR BIOLABS
- Table 6-35: Vector Biolabs Corporate Summary
- Company Overview
- Products
VIGENE BIOSCIENCES
- Table 6-36: Vigene Biosciences Corporate Summary
- Company Overview
- Products
VIROCELL BIOLOGICS
- Table 6-37: ViroCell Biologics Corporate Summary
- Company Overview
- Products
VIROVEK
- Table 6-38: Virovek Corporate Summary
- Company Overview
- Products
VOYAGER THERAPEUTICS
- Table 6-39: Voyager Therapeutics Corporate Summary
- Company Overview
- Products
WAISMAN BIOMANUFACTURING
- Table 6-40: Waisman Biomanufacturing Corporate Summary
- Company Overview
- Products
YPOSKESI
- Table 6-41: Yposkesi Corporate Summary
- Company Overview
- Products
Companies Mentioned
- 4D Molecular Therapeutics, Inc. (4DMT)
- ABL Inc
- AGC Biologics
- Agilent Technologies
- Aldevron
- Batavia Biosciences B.V.
- Biovian Oy
- Catapult Cell and Gene Therapy
- Cevec Pharmaceuticals GmbH
- Cobra Biologics
- Cytiva Life Sciences
- Finvector Oy
- Fujifilm Diosynth Biotechnologies
- Genezen
- Horizon Discovery Ltd.
- Lonza
- Merck Kgaa/Millipore Sigma
- Mirus Bio
- Oxford Biomedica plc.
- Regenxbio, Inc
- Sanofi S.A.
- Sirion Biotech
- Spark Therapeutics, Inc
- Takara Bio
- Thermo Fisher Scientific
- Uniqure N.V.
- Vector Biolabs
- Vigene Biosciences
- Virocell Biologics
- Virovek
- Voyager Therapeutics
- Waisman Biomanufacturing
- Yposkesi
